[Federal Register Volume 78, Number 20 (Wednesday, January 30, 2013)]
[Notices]
[Pages 6330-6331]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-01975]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Clinical Laboratory Improvement Advisory Committee (CLIAC)

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following meeting of the aforementioned 
committee:

Times and Dates

8:30 a.m.-5 p.m., March 6, 2013
8:30 a.m.-12 p.m., March 7, 2013

    Place: CDC, 1600 Clifton Road, NE., Tom Harkin Global 
Communications Center, Building 19, Room 232, Auditorium B, Atlanta, 
Georgia 30333.
    Online Registration Required: All CLIAC attendees are required to 
register for the meeting online at least 5 business days in advance for 
U.S. citizens and at least 10 business days in advance for 
international registrants. Register at http://wwwn.cdc.gov/cliac/default.aspx by scrolling down and clicking the appropriate link under 
``Meeting Registration'' (either U.S. Citizen Registration or Non-U.S. 
Citizen Registration) and completing all forms according to the 
instructions given. Please complete all the required fields before 
submitting your registration and submit no later than February 27, 2013 
for U.S. registrants and February 20, 2013 for international 
registrants.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 100 people.
    Purpose: This Committee is charged with providing scientific and 
technical advice and guidance to the Secretary of Health and Human 
Services; the Assistant Secretary for Health; the Director, Centers for 
Disease Control and Prevention; the Commissioner, Food and Drug 
Administration; and the Administrator, Centers for Medicare and 
Medicaid Services. The advice and guidance pertain to general issues 
related to improvement in clinical laboratory quality and laboratory 
medicine practice and specific questions related to possible revision 
of the CLIA standards. Examples include providing guidance on studies 
designed to improve safety, effectiveness, efficiency, timeliness, 
equity, and patient-centeredness of laboratory services; revisions to 
the standards under which clinical laboratories are regulated; the 
impact of proposed revisions to the standards on medical and laboratory 
practice; and the modification of the standards and provision of non-
regulatory guidelines to accommodate technological advances, such as 
new test methods and the electronic transmission of laboratory 
information.
    Matters To Be Discussed: The agenda will include agency updates 
from CDC, the Centers for Medicare & Medicaid Services (CMS), and the 
Food and Drug Administration (FDA). Presentations and discussions will 
include activities related to forthcoming FDA infection prevention 
guidance for the use of fingerstick and point-of-care blood testing 
devices, especially glucose meters. Other topics will include the 
harmonization of clinical laboratory test results; and assuring the 
quality of new DNA sequencing technologies in the clinical laboratory.
    Agenda items are subject to change as priorities dictate.
    Providing Oral or Written Comments: It is the policy of CLIAC to 
accept written public comments and provide a brief period for oral 
public comments whenever possible. Oral Comments: In general, each 
individual or group requesting to make an oral presentation will be 
limited to a total time of five minutes (unless otherwise indicated). 
Speakers must also submit their comments in writing for inclusion in 
the meeting's Summary Report. To assure adequate time is scheduled for 
public comments, individuals or groups planning to make an oral 
presentation should, when possible, notify the contact person below at 
least one week prior to the meeting date. Written Comments: For 
individuals or groups unable to attend the meeting, CLIAC accepts 
written comments until the date of the meeting (unless otherwise 
stated). However, it is requested that comments be submitted at least 
one week prior to the meeting date so that the comments may be made 
available to the Committee for their consideration and public 
distribution. Written comments, one hard copy with original signature, 
should be provided to the contact person below. Written comments will 
be included in the meeting's Summary Report.
    Availability of Meeting Materials: To support the green initiatives 
of the federal government, the CLIAC meeting materials will be made 
available to the Committee and the public in electronic format (PDF) on 
the Internet instead of by printed copy. Refer to the CLIAC Web site on 
the day of the meeting for materials. http://wwwn.cdc.gov/cliac/cliac_meeting_all_documents.aspx.

    Note: If using a mobile device to access the materials, please 
verify the device's browser is able to download the files from the 
CDC's Web site before the meeting. Alternatively, the files can be 
downloaded to a computer and then emailed to the portable device. An 
Internet connection, power source and limited hard copies may be 
available at the meeting location, but cannot be guaranteed.

    Contact Person for Additional Information: Nancy Anderson, Chief, 
Laboratory Practice Standards Branch, Division of Laboratory Science 
and Standards, Laboratory Science, Policy and Practice Program Office, 
Office of Surveillance, Epidemiology and Laboratory Services, Centers 
for Disease Control and Prevention, 1600 Clifton Road NE., Mailstop F-
11, Atlanta, Georgia 30333; telephone (404) 498-2741; fax (404) 498-
2219; or via email at [email protected].
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register Notices pertaining to 
announcements of meetings and other committee management activities, 
for CDC and the

[[Page 6331]]

Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2013-01975 Filed 1-29-13; 8:45 am]
BILLING CODE 4163-18-P